Skip to main content
. Author manuscript; available in PMC: 2009 Mar 20.
Published in final edited form as: Mol Ther. 2008 Aug 5;16(10):1745–1752. doi: 10.1038/mt.2008.161

Figure 7. The RT9-hFIX/PGK-MGMT hematopoietic stem cell-based gene therapy paradigm.

Figure 7

Dual-gene expressing lentiviral vector system allows nonlineage specific methylguanine methyltransferase (MGMT) P140K drug-resistant gene expression driven by a (a) relatively weak human phosphoglycerate kinase promoter in all cells and (b) as well as high-level protein delivery in late stage erythroid cells.